Leap Therapeutics Enters $200M Equity Sales Agreement
I'm PortAI, I can summarize articles.
Leap Therapeutics (LPTX) has entered a $200 million Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. This agreement allows the company to sell shares of its common stock under its shelf registration statement. The latest analyst rating for LPTX is a Hold with a $1.25 price target, while Spark's AI Analyst rates it as Underperform due to financial challenges and bearish technical trends. The current market cap is $26.03 million, with an average trading volume of 3,541,541 shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments